FDA Rejects AMT-130 Phase I/II Data for Marketing Application, Recommends Phase III Study
QURE sits 16% above its 52-week low of $7.76 on elevated volume (2.4× avg).
Summary
The FDA has rejected uniQure's Phase I/II data for AMT-130 as insufficient for a marketing application, requiring a full Phase III trial, significantly delaying its lead program. The company also reported an extended cash runway but faced setbacks in other pipeline candidates.
Key Events · Product Development and Regulatory · QURE
-
FDA Rejects AMT-130 Phase I/II Data for Marketing Application
The U.S. Food and Drug Administration (FDA) informed uniQure that its Phase I/II study data for AMT-130, an investigational gene therapy for Huntington's disease, is not sufficient to support a marketing application.
-
FDA Recommends Full Phase III Study
The FDA strongly recommended uniQure conduct a prospective, randomized, double-blind, sham surgery-controlled Phase III study, significantly extending the development timeline and costs for the lead candidate.
-
Extended Cash Runway into Second Half of 2029
The company reported cash, cash equivalents, and current investment securities of $622.5 million as of December 31, 2025, which is expected to fund operations into the second half of 2029, largely due to prior public offerings.
-
Setbacks in Other Pipeline Programs
Dosing in mid- and high-dose cohorts for AMT-191 (Fabry disease) has been paused due to dose-limiting toxicities, and enrollment for AMT-162 (ALS) remains on voluntary pause following a serious adverse event.
Analysis · QURE · Life Sciences
uniQure N.V. announced a significant regulatory setback for its lead gene therapy candidate, AMT-130 for Huntington's disease. The FDA has stated that the Phase I/II study data, even with positive 36-month results, is insufficient to support a marketing application and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled Phase III study. This decision significantly delays the potential market entry for AMT-130 and will require substantial additional investment in a lengthy clinical trial. While the company reported a strong cash position of $622.5 million, extending its runway into the second half of 2029, this capital will now be needed to fund the newly required Phase III trial. Additionally, other pipeline programs, AMT-191 and AMT-162, reported safety concerns leading to paused dosing or enrollment, adding to the overall negative sentiment regarding the company's clinical progress.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.7% of the 583 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QURE was trading at $8.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $962.9M. The 52-week trading range was $7.76 to $71.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.